Dutch biotechnology company Pharming announced on Tuesday that it has signed a distribution agreement with the Turkish pharmaceutical company EIP for its medicine Rhucin. No financial details were disclosed.

The agreement is remarkable, according to the Financieele Dagblad, because Pharming was told by the European medicines agency last week that it would receive a negative reply to its marketing authorisation application for Rhucin.
Rhucin is used in the treatment of acute attacks of hereditary angioedema.